Net margin is calculated as Net Income divided by its Revenue. VivoSim Labs's Net Income for the
three
months ended in Dec. 2025 was €-2.30 Mil. VivoSim Labs's Revenue for the
three
months ended in Dec. 2025 was €0.02 Mil. Therefore, VivoSim Labs's net margin for the quarter that ended in Dec. 2025 was -10,445.45%.
The historical rank and industry rank for VivoSim Labs's Net Margin % or its related term are showing as below:
FRA:4OR'
s Net Margin % Range Over the Past 10 Years
Min: -13459.63 Med: -908.91 Max: -756.09
Current: -864.09
FRA:4OR's Net Margin % is ranked worse than 77.51% of 947
companies
in the Biotechnology industry
Industry Median: -89.56
vs FRA:4OR: -864.09
VivoSim Labs (FRA:4OR) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
VivoSim Labs Net Margin % Related Terms
VivoSim Labs Net Margin % Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4OR vs AZTR, GRI, BIXT: Net Margin % Comparison
For the Biotechnology subindustry, VivoSim Labs's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's Net Margin % distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VivoSim Labs (FRA:4OR) has a Net Margin % of -10,445.45% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on VivoSim Labs and its competitors. According to the industry distribution chart, VivoSim Labs ranks #734 out of 947 companies in the Biotechnology industry, placing it in the top 77.5%.
Is VivoSim Labs' Net Margin % too high?
VivoSim Labs' current Net Margin % is -10,445.45%. Based on the distribution chart, VivoSim Labs ranks #734 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Net Margin % compare to AZTR and GRI?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #734 out of 947 companies for Net Margin %. This places VivoSim Labs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on VivoSim Labs and its competitors. VivoSim Labs's current Net Margin % is -10,445.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Net Margin % of -10,445.45%. The stock's GF Value™ is €8.13, compared to a current price of €3.49 — trading 57% below its estimated fair value. The current Net Margin % is -10,445.45%. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Net Margin % is -10,445.45% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 57% below its estimated GF Value™ of €8.13.
Key valuation signals for FRA:4OR:
Net Margin %: -10,445.45%
GF Value™: €8.13 vs. price of €3.49 (57% below fair value)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score
Get the complete analysis for FRA:4OR
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
